Article

Blood Pressure Lowering for the Prevention of Stroke Recurrence

Register or Login to View PDF Permissions
Permissions× For commercial reprint enquiries please contact Springer Healthcare: ReprintsWarehouse@springernature.com.

For permissions and non-commercial reprint enquiries, please visit Copyright.com to start a request.

For author reprints, please email rob.barclay@radcliffe-group.com.

  • Views: 417

  • Likes: 0

  • Downloads: 1

  • Citations: 1

Average (ratings)
No ratings
Your rating

Abstract

Stroke is the second most common cause of mortality worldwide. It is the complication of hypertension that has the most direct link to blood pressure. Hypertension affects nearly 30% of the world’s population. In addition to hypertension, a previous history of cerebrovascular disease is a powerful predictor of stroke recurrence. In a meta-analysis of 10 trials of patients with previous cerebrovascular disease, bloodpressure- lowering treatment reduced systolic blood pressure (ΔSBP) by 5.1mmHg and the risk of stroke recurrence by 22% (p=0.0007) compared with no treatment or placebo. In four trials involving diuretics as a component of therapy (ΔSBP 9.6mmHg), the pooled reduction of stroke recurrence averaged 37% (p<0.0001), whereas it was only 7% in six trials of renin system inhibitors (ΔSBP 4.0mmHg). In metaregression analysis, the weighted correlation co-efficient between the odds for stroke recurrence and the blood pressure reduction was -0.57 (p=0.067). The significant heterogeneity (p<0.0001) between diuretics and renin system inhibitors in the prevention of stroke recurrence might be explained by the greater blood pressure reduction of treatments including diuretics. Our results do not support the use of renin system inhibitors for the prevention of stroke recurrence.

Keywords

Blood pressure lowering, stroke prevention, hypertension, eprosartan, nitrendipine, MOSES study,

Disclosure:Jan A Staessen has consulted for pharmaceutical companies and received funding for studies, seminars and travel from manufacturers of drugs that lower blood pressure. The remaining authors have no conflicts of interest to declare.

Received:

Accepted:

DOI:https://doi.org/10.15420/ecr.2010.6.1.37

Acknowledgements:The authors gratefully acknowledge the expert assistance of Sandra Covens and Ya Zhu (Studies Co-ordinating Centre, Leuven, Belgium).

Correspondence Details:Jan A Staessen, Studies Co-ordinating Centre, Division of Hypertension and Cardiovascular Rehabilitation, Department of Cardiovascular Diseases, University of Leuven, Campus Sint Rafaël, Kapucijnenvoer 35, Block D, Level 00, B-3000 Leuven, Belgium. E: jan.staessen@med.kuleuven.be or ja.staessen@epid.unimaas.nl

Copyright Statement:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Stroke is the second most common cause of mortality worldwide.1 Cerebrovascular disease caused an estimated 5.7 million deaths in 2005, with 87% occurring in low- or middle-income countries.2 Without intervention, the global number of stroke deaths will rise to 6.5 million in 2015 and 7.8 million in 2030.2 Blood pressure is the most consistent and powerful predictor of stroke. Hypertension affects nearly 30% of the world’s population.3,4 Population mortality trends for stroke parallel those in hypertension.5,6 In addition to hypertension, a previous history of cerebrovascular disease is a powerful predictor of stroke recurrence.1 The purpose of our review was to summarise the evidence in favour of blood pressure lowering for the prevention of stroke recurrence.

Search Strategy

We identified original research papers on the prevention of stroke recurrence by systematically searching the table of contents (January 2000 until January 2009) of general interest and speciality journals that publish clinical research on hypertension or cerebrovascular disease. We searched the PubMed database (www.ncbi.nlm.nih.gov/sites/entrez) for publications in English or with English abstracts. Starting from the preview/index tab, we chose the following as search terms for titles and abstracts: blood pressure, hypertension, stroke, haemorrhagic stroke, ischaemic stroke, recurrent stroke or any combination of these index terms. We also checked the reference lists of review papers for updates of clinical trials.

Active Treatment Compared with Placebo or No Treatment

As reported in detail elsewhere,7 10 randomised controlled trials8–17 investigated the effects of antihypertensive drug treatment versus no treatment or placebo on recurrent stroke in hypertensive or normotensive patients with a history of cerebrovascular disease. We extracted the characteristics of the 10 trials and those of the enrolled patients with a history of stroke from specific publications on stroke recurrence8–17 or from articles describing the baseline data18 or main results19,20 of the reviewed trials. We combined the results of the 10 trials8–17 on the secondary prevention of stroke (11 groups of randomised patients) in stratified 2x2 tables. We computed pooled odds ratios from fixed effect models or, in the case of significant heterogeneity, from random effect models. In subgroup analysis, we contrasted trials that used a diuretic9–11,14 as opposed to renin system inhibitors8,12–16 as the mainstay of active treatment.

Renin system inhibitors, in addition to angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers, also included β-blockers.21,22 We used the PROC MIXED procedure as implemented in the SAS package, version 9.1.3 (SAS Institute, Carey, NC, US). We weighted pooled estimates of the odds ratios by the inverse of the variance of the odds ratios in individual studies and pooled estimates of the gradients in blood pressure by the number of patients randomised in each trial. We computed the weighted correlation between the odds of stroke recurrence on active treatment and the gradient in systolic blood pressure between groups (active treatment minus control) randomised in the 10 trials.8–17

In three early trials11–13 in which either methylclothiazide combined with deserpidine11 or atenolol12,13 was compared with placebo, the average reductions in blood pressure ranged from 413 to 25mmHg11 systolic and from 312,13 to 12mmHg11 diastolic (see Figure 1). These three studies11–13 could not confirm the significant 67% benefit on stroke recurrence (p=0.02) initially reported by Carter in a much smaller trial.10 In 1,520 Chinese Perindopril PrOtection Against Recurrent Stroke Study (PROGRESS) patients, active treatment – consisting of indapamide (2.5mg per day), which in most centres was combined with perindopril (4mg per day) – reduced blood pressure by 14mmHg systolic and 6mmHg diastolic and stroke recurrence by 55% (95% confidence interval [CI] 40–65%).14,23 In the Heart Outcomes Prevention Evaluation trial (HOPE),15 1,013 patients with a history of cerebrovascular disease were randomised to ramipril (up to 10mg daily) or matching placebo, given on top of unspecified background therapy. Compared with placebo, ramipril reduced blood pressure by 3.1mmHg systolic and 1.7mmHg diastolic, but the relative risk reduction of 15% in stroke recurrence was not significant (CI -42–30%). The Felodipine EVEnt Reduction study (FEVER) included 2,368 Chinese patients with a history of cerebrovascular disease (24.2% of 9,800 randomised patients).17 FEVER patients whose blood pressure on treatment with hydrochlorothiazide 12.5mg per day remained in the range of 140–180mmHg systolic or 90–100mmHg diastolic were randomised to extended-release felodipine 5mg per day or placebo.17 In the post-stroke FEVER patients, felodipine reduced blood pressure by 4.0mmHg systolic and 1.8mmHg diastolic (see Figure 1), but the odds ratio for stroke recurrence on felodipine versus placebo was not significant (0.81, CI 0.58–1.13).

In the Prevention Regimen For Effectively avoiding Second Strokes (PRoFESS) trial,8 addition of telmisartan (80mg daily) to the background treatment in patients with an ischaemic stroke did not significantly reduce the incidence of recurrent stroke compared with placebo (-5%, CI -14–4%; p=0.23) or major cardiovascular events (-6%, CI -13–1%; p=0.11).

We combined the results of the 10 trials8–17 (see Figure 1). Overall, the odds ratio for the prevention of stroke recurrence by blood-pressure-lowering therapy was 0.78 (CI 0.68–0.90; p=0.0007). The pooled odds ratio was 0.63 (CI 0.54–0.73; p<0.0001) for trials involving a diuretic as a component of experimental therapy,9–13,14 and 0.93 (CI 0.87–1.01; p=0.086) in the trials8,13–16 in which the mainstay of treatment consisted of inhibition of the renin system by atenolol,12,13 perindopril,14 ramipril,15 candesartan16 or telmisartan.8 The p-value for heterogeneity between studies involving diuretics compared with renin system inhibitors was <0.0001. There was also heterogeneity in the odds ratios among all trials (p=0.0004; see Figure 1). In the four trials of diuretics in monotherapy (PATS) or combined with anti-adrenergic agents10,11 or perindopril,14 the blood pressure reduction averaged 8.5mmHg systolic and 3.6mmHg diastolic. In the six studies of renin system inhibitors,8,12–16 usually given on top of background treatment, the blood pressure decreased on average by 4.0mmHg systolic and 2.1mmHg diastolic. In all studies combined,8–17 the blood pressure reduction averaged 5.1mmHg systolic and 2.5mmHg diastolic (see Figure 1). In weighted regression analysis, the correlation between the odds of stroke recurrence and the reduction in systolic blood pressure approached significance. The correlation coefficient was -0.58 (p=0.081) across 10 groups and -0.57 (p=0.067) when for Carter’s trial a reduction in systolic blood pressure of 10mmHg was attributed to active treatment (11 groups).

Comparison Between Eprosartan and Nitrendipine

The MOSES study (Morbidity and Mortality after Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention)24 included 1,405 hypertensive patients with a cerebrovascular event within two years of randomisation. MOSES compared the only registered daily dose of eprosartan (600mg) with a suboptimal dose of nitrendipine.

Mean daily doses at the end of the trial were 623mg for eprosartan and 16.2mg for nitrendipine.24 For comparison, in the Systolic Hypertension in Europe Trial,25 the daily dose of nitrendipine averaged approximately 30mg. In MOSES,24 the primary outcome was the composite of total mortality and all cardiovascular and cerebrovascular events, including recurrent events. The incidence density ratio comparing eprosartan with nitrendipine was 0.79 (CI 0.66–0.96; p=0.014) for the composite end-point and 0.75 (CI 0.58–0.97; p=0.026) for stroke recurrence.24 In state-of- the-art actuarial analyses only considering time to the first event within each category (with censoring), the hazard ratios were 0.69 (CI 0.50–0.97; p=0.031) for cardiovascular events and 0.88 (CI 0.65–1.20; p=0.42) for the first recurrent cerebrovascular complication.24

Interpretation

In our meta-analysis (see Figure 1), blood-pressure-lowering treatment across 10 trials (11 groups), including the perindopril only and the perindopril combined with indapamide arms of the PROGRESS trial,8 reduced the risk of recurrent stroke by 22%. In the trials involving diuretics as a component of therapy,9–11,14 the pooled reduction averaged 37%, whereas it was only 7% in the trials of renin system inhibitors.8,12–15 As suggested by our meta-regression analysis, the significant heterogeneity (p<0.0001) between diuretics and renin system inhibitors in the prevention of stroke recurrence might be explained by the larger blood pressure reduction on treatment regimens involving diuretics. Whatever mechanism underlies the benefit of indapamide in the secondary7 and primary26 prevention of stroke, our meta-analysis does not support the recommendation that prevention of stroke recurrence is a compelling indication for the use of angiotensin-converting enzyme inhibitors.27

References

  1. Lopez AD, Mathers CD, Ezzqati M, et al., Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data, Lancet, 2006;367:1747–57.
    Crossref | PubMed
  2. Strong K, Mathers C, Bonita R, Preventing stroke: saving lives around the world, Lancet Neurol, 2007;6:182–7.
    Crossref | PubMed
  3. Mackay J, Mensah G, The Atlas of Heart Disease and Stroke, World Health Organization, Geneva, Switzerland, 2004.
  4. Staessen JA, Wang J, Bianchi G, Birkenhäger WH, Essential hypertension, Lancet, 2003;361:1629–41.
    Crossref | PubMed
  5. Luepker RV, Arnett DK, Jacobs DR, Jr, et al., Trends in blood pressure, hypertension control, and stroke mortality: the Minnesota Heart survey, Am J Med, 2006;119:42–9.
    Crossref | PubMed
  6. Wolf-Maier K, Cooper RS, Banegas JR, et al., Hypertension prevalence and blood-pressure levels in 6 European countries, Canada, and the United States, JAMA, 2003;289:2363–9.
    Crossref | PubMed
  7. Liu L, Wang Z, Gong L, et al.; for the Post-stroke Antihypertensive Treatment Study (PATS) Investigators, Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature, Hypertens Res, 2009;32:1032–40.
    Crossref | PubMed
  8. Yusuf S, Diener HC, Sacco RL, et al.; for the PRoFESS Study Group. Telmisartan to prevent recurrent stroke and cardiovascular events, N Engl J Med, 2008;359:1225–37.
    Crossref | PubMed
  9. PATS Collaborative Group, Post-stroke antihypertensive treatment study. A preliminary result, Chin Med J, 1995;108:710–17.
    PubMed
  10. Carter AB, Hypotensive therapy in stroke survivors, Lancet, 1970;1:485–9.
    Crossref | PubMed
  11. Hypertension-Stroke Cooperative Study Group, Effect of antihypertensive treatment on stroke recurrence, JAMA, 1974;229:409–18.
    Crossref | PubMed
  12. The Dutch TIA Trial Study Group, Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke, Stroke 1993;24:543–8.
    Crossref | PubMed
  13. Eriksson S, Olofsson BO, Wester PO; for the TEST study group, Atenolol in secondary prevention after stroke, Cerebrovasc Dis, 1995;5:21–5.
    Crossref
  14. PROGRESS Collaborative Group, Randomised trial of a perindopril-based blood-pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack, Lancet, 2001;358:1033–41.
    Crossref | PubMed
  15. Bosch J, Yusuf S, Pogue J, et al.; on behalf of the HOPE Investigators. Use of ramipril in preventing stroke: double blind randomised trial, BMJ, 2002;324:1–5.
  16. Trenkwalder P, Elmfeldt D, Hofman A, et al., The Study on COgnition and Prognosis in the Elderly (SCOPE) – major CV events and stroke in subgroups of patients, Blood Press, 2005;14:31–7.
    Crossref | PubMed
  17. Liu L, Zhao Y, Liu G, et al.; for the FEVER Study Group. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients, J Hypertens, 2005;23:2157–72.
    Crossref | PubMed
  18. PROGRESS Management Committee, PROGRESS – Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline, J Hypertens, 1999;17:1647–55.
    Crossref | PubMed
  19. The Heart Outcomes Prevention Evaluation Study Investigators, Effects of an angiotensin-convertingenzyme inhibitor, ramipril, on cardiovascular events in high-risk patients, N Engl J Med, 2000;342:145–53.
    Crossref | PubMed
  20. Lithell H, Hansson L, Skoog I, et al.; for the SCOPE Study Group. The study on cognition and prognosis in the elderly (SCOPE). Principal results of a randomised double-blind intervention trial, J Hypertens, 2003;21:875–86.
    Crossref | PubMed
  21. Holmer SR, Hense HW, Danser AHJ, et al., β-Adrenergic blockers lower renin in patients treated with ACE inhibitors and diuretics, Heart, 1998;80:45–8.
    Crossref | PubMed
  22. Staessen JA, Li Y, Richart T, Oral renin inhibitors, Lancet, 2006;346:1449–56.
    Crossref | PubMed
  23. Liu LS, Gong LS, Wang W; Blood Pressure Lowering to Prevent Recurrent Stroke Study Group, Effects of blood pressure lowering treatment on stroke recurrence in patients with cerebrovascular diseases—a large-scale, randomized, placebo controlled trial, Chin J Cardiol, 2005;33: 613–17.
  24. Schrader J, Luders S, Kulschewski A, et al., Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES), Stroke, 2005;36:1218–26.
    Crossref | PubMed
  25. Staessen JA, Fagard R, Thijs L, et al., Randomised doubleblind comparison of placebo and active treatment for older patients with isolated systolic hypertension, Lancet, 1997;350:757–64. Erratum: Lancet, 1997;350:1636.
    Crossref | PubMed
  26. Beckett NS, Peters R, Fletcher AE, et al.; for the HYVET Study Group. Treatment of hypertension in patients 80 years of age or older, N Engl J Med, 2008;358:1887–98.
    Crossref | PubMed
  27. Chobanian AV, Bakris GL, Black HR, et al., Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure, Hypertension, 2003;42:1206–52.
    Crossref | PubMed
Previous Volume Article Next Volume Article